Gilead Sciences, Inc. vs Moderna, Inc.: Strategic Comparison

This in-depth comparison examines Gilead Sciences, Inc. and Moderna, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Gilead Sciences, Inc. on its own, evaluating Moderna, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Gilead Sciences, Inc. and Moderna, Inc. is widest.

On the headline numbers, annual revenue is $29.4B (FY2025) for Gilead Sciences, Inc. and $1.9B (FY2025) for Moderna, Inc., while their respective market capitalizations stand at $180.0B and $72.7B. Both Gilead Sciences, Inc. and Moderna, Inc. are headquartered in United States. Their local markets and applicable rules may still differ.

Gilead Sciences, Inc.: Gilead Sciences is one of the largest US biotechnology companies, with about 17,000 employees and a market value near $180B in September 2026. It turned HIV into a manageable chronic disease with tenofovir-based medicines, cured most hepatitis C patients with Sovaldi and Harvoni, and supplied the first approved COVID-19 antiviral, Veklury. Today HIV accounts for roughly 71% of revenue, with oncology and liver disease making up most of the rest. The company is headquartered in Foster City, California.

Moderna, Inc.: Moderna, Inc. is a Nasdaq-listed biotechnology company headquartered in Cambridge, Massachusetts. It develops medicines that deliver mRNA instructions into cells so the body produces a target protein, such as a viral antigen or tumor neoantigen. As of 2026 it markets COVID-19 vaccines (Spikevax, mNEXSPIKE), an RSV vaccine (mRESVIA) and a flu vaccine (mFLUSIVA), and co-develops the individualized cancer therapy intismeran autogene with Merck.

Gilead Sciences, Inc. and Moderna, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Gilead Sciences, Inc. and Moderna, Inc..

Gilead Sciences, Inc. business model: Gilead discovers, licenses or acquires drug candidates, takes them through clinical trials and regulatory approval, then sells them through wholesalers, pharmacies and hospitals under patent protection. Product sales were $28.9B of FY2025 revenue, with the rest coming from royalties and contract income. HIV is the profit engine: Biktarvy is a once-daily single tablet that patients typically take for years, which makes revenue recurring. Non-GAAP product gross margin was 86.4% in 2025, and Gilead spent $5.8B on R&D plus about $1.0B on acquired in-process R&D. Large acquisitions such as Pharmasset (2011), Kite (2017), Immunomedics (2020), CymaBay (2024) and Arcellx (2026) have supplied most of its new franchises.

Moderna, Inc. business model: Moderna earns most of its revenue from net product sales of mRNA vaccines: Spikevax and mNEXSPIKE for COVID-19, mRESVIA for RSV, and from the 2026-2027 season mFLUSIVA for influenza. Buyers are governments, national immunization programs, pharmacy chains, wholesalers and health systems, so sales are concentrated in the autumn and winter vaccination season. Smaller amounts come from collaboration, licensing and grant revenue. Because every product uses the same mRNA and lipid nanoparticle backbone, Moderna can reuse manufacturing, regulatory and clinical know-how across programs, while partners such as Merck share development costs and profits on the individualized cancer vaccine intismeran autogene.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Gilead Sciences, Inc. stack up against those of Moderna, Inc..

Gilead Sciences, Inc. competitive advantage: Gilead's moat is three decades of antiviral chemistry and HIV clinical data. Tenofovir-based backbones, Biktarvy's single-tablet convenience and a high barrier to resistance made it the most prescribed HIV regimen in the US, and lenacapavir gave Gilead the first twice-yearly HIV prevention injection (Yeztugo, FDA approved June 2025). Its scale in HIV sales and payer contracting, plus about $10.6B of cash and marketable securities at the end of 2025, lets it fund acquisitions without depending on one deal.

Moderna, Inc. competitive advantage: Moderna's advantages are a validated mRNA and lipid nanoparticle platform, a large patent estate on modified mRNA, in-house manufacturing in Norwood, Massachusetts plus onshore plants in the UK, Canada and Australia, and regulatory experience across approved respiratory products. The same platform produced the first FDA-approved mRNA flu vaccine (2026) and the first individualized neoantigen therapy to succeed in a Phase 3 trial.

Future prospects matter as much as current results. The growth strategies below explain how Gilead Sciences, Inc. and Moderna, Inc. each plan to expand from here.

Gilead Sciences, Inc. growth strategy: Gilead's growth plan has four parts: expand HIV prevention with Yeztugo and Descovy, defend HIV treatment with next-generation regimens such as bictegravir/lenacapavir, grow liver disease with Livdelzi, and buy into oncology and inflammation. In 2025 it acquired Interius BioTherapeutics for in vivo CAR-T. In 2026 it closed Arcellx (about $7.8B implied equity value), Tubulis ($3.15B upfront, up to $1.85B in milestones) and Ouro Medicines ($1.675B upfront, with Lakefront) to rebuild its pipeline.

Moderna, Inc. growth strategy: Moderna is narrowing its pipeline to programs with near-term commercial potential: respiratory vaccines (COVID, RSV, flu and combinations), individualized cancer therapy with Merck, and a small set of rare-disease and latent-virus programs. It cut R&D spending, reduced headcount below 5,000 in 2025, and is seeking expanded age and country approvals for existing vaccines while preparing filings for intismeran autogene.

A closer look at the financial trajectory of Gilead Sciences, Inc. and Moderna, Inc. rounds out the comparison.

Gilead Sciences, Inc.: Gilead's revenue history tracks its product cycles. Hepatitis C cures Sovaldi and Harvoni lifted revenue to $30.4B in 2016, then sales fell as patients were cured, bottoming at $22.1B in 2018. HIV growth and pandemic Veklury sales took revenue back to $27.3B in 2021, and it has since grown slowly to $28.8B in 2024 and $29.4B in 2025. Net income swings with deal accounting: it was only $480M in 2024 because of the CymaBay IPR&D charge, then recovered to $8.5B ($6.78 diluted EPS) in 2025. In Q2 2026 revenue rose 10% to $7.8B, but more than $11B of acquired IPR&D, mainly from Arcellx, produced a GAAP loss of $8.45 per share. February 2026 guidance called for $29.6B to $30.0B in 2026 product sales. Gilead Sciences, Inc. is a massive American biopharmaceutical company, commanding a market valuation typically over $80 billion.

Moderna, Inc.: Moderna went from $803 million of revenue in 2020 to $18.5 billion in 2021 and $19.3 billion in 2022, earning $12.2 billion and $8.4 billion of net income in those years. Revenue then fell to $6.8 billion in 2023, $3.2 billion in 2024 and $1.94 billion in 2025, with net losses of $4.7 billion, $3.6 billion and $2.8 billion. In 2025 Moderna cut operating expenses by about $2.2 billion (roughly 30%) and ended the year with $8.1 billion in cash and investments. Q2 2026 revenue was $145 million with a $782 million net loss; management guided to up to 10% revenue growth for 2026 and cash costs of about $4 billion. Moderna, Inc. is a major American pharmaceutical and biotechnology company pioneering messenger RNA (mRNA) therapeutics, sustaining a market valuation typically over $40 billion.